



### Corporate Information

### **Board Of Directors**

Munir A. Shaikh (Chairman)
Arshad Saeed Husain
(Chief Executive Officer)
Kamran Y. Mirza
Thomas C. Freyman
(Alternate Director Anis A. Shah)
Syed Anis Ahmed
Angelo Kondes
Shamim Ahmad Khan

### **Audit Committee**

Shamim Ahmad Khan (Chairman) Munir A. Shaikh Kamran Y. Mirza Maria Memon (Chief Internal Auditor by Invitation) Syed Anis Ahmed (CFO by Invitation)

## Human Resource and Remuneration Committee

Munir A. Shaikh (Chairman) Arshad Saeed Husain Shamim Ahmad Khan Shahrukh Masood

### **Share Transfer Committee**

Arshad Saeed Husain (Chairman) Syed Anis Ahmed Anis A. Shah (Alternate Director to Thomas C. Freyman)

### **Banking Committee**

Munir A. Shaikh (Chairman) Arshad Saeed Husain Anis A. Shah (Alternate Director to Thomas C. Freyman) Syed Anis Ahmed

### Chief Financial Officer

Syed Anis Ahmed

### Company Secretary

Malik Saadatullah

### **Auditors**

M. Yousuf Adil Saleem & Co. Chartered Accountants

### Legal Advisors

Orr, Dignam & Co. Surridge & Beecheno

### Share Registrar

FAMCO Associates (Pvt) Ltd. State Life Building, 1-A,1st Floor, I.I. Chundrigar Road, Karachi-74000

### Bankers

Faysal Bank Limited
Citibank N.A.
Deutsche Bank AG
MCB Bank Limited
National Bank of Pakistan
Standard Chartered Bank
(Pakistan) Limited
HSBC Bank Middle East Limited
The Bank of Tokyo-Mitsubishi UFJ Limited
Barclays Bank PLC

### City Office

8th Floor, Faysal House, St-02, Shahrah-e-Faisal, Karachi

### Registered Office

Opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, P.O. Box 7229, Karachi

#### Website

www.abbott.com.pk

### Senior Management Team

Arshad Saeed Husain (Chief Executive Officer) Syed Anis Ahmed (Chief Financial Officer) Anis A. Shah (Operations Director) Ayub A. Siddiqui (Head of Nutrition Division) Habib Ahmed (Head of Diagnostics Division) Dr. Farrukh Hafeez (Quality Assurance Director) Shahrukh Masood (Human Resource Director) Seema Khan (Regulatory Director) Dr. Sarmad Magbool (Marketing & Strategy Director) Dr. Raeef Ahmed (Medical Director)

### Directors' Report

The Directors have pleasure in presenting their Report with the accounts of the Company for the second quarter ended June 30th, 2013.

### FINANCIAL RESULTS

Sales for the quarter increased by 13% over the same quarter last year. Pharmaceutical sales increased by 13% & others grew by 11%. Gross profit to sales ratio remained at 40%. Selling and distribution expenses increased by 15% mainly due to inflation and increase in fuel prices. Other charges increased due to increase in the provision for Workers Profits Participation Fund, Workers Welfare Fund and Central Research Fund.

### **FUTURE OUTLOOK**

Increasing energy prices, inflation and devaluation of the Pak Rupee continue to remain a source of concern for the Industry. It is essential for the Government to consider allowing across the board price increase to offset impact of devaluation and inflation. It also behooves the government to decontrol prices of non-essential pharmaceutical products to enable availability of Pharmaceutical products to patients and the development of the Pharmaceutical industry.

KARACHI: August 19th, 2013

Munir A. Shaikh Chairman

### Deloitte.

M. Yousuf Adil Saleem & Co. Chartered Accountants Cavish Court, A-35, Block 7 & 8 KCHSU, Sharea Faisal, Karachi-75350 Pakistan

Phone: +92 (0) 21-34546494-7 Fax: +92 (0) 21-3454 1314 Web: www.deloitte.com

## Auditors' Report to the Members on Review of Interim Financial Information

#### Introduction

We have reviewed the accompanying condensed interim balance sheet of ABBOTT LABORATORIES (PAKISTAN) LIMITED (the Company) as at June 30, 2013 and the related condensed interim profit and loss account, condensed interim statement of comprehensive income, condensed interim cash flow statement, condensed interim statement of changes in equity and notes to the condensed interim financial information for the six months then ended (here-in-after referred to as the "interim financial information"). Management is responsible for the preparation and presentation of this interim financial information in accordance with approved accounting standards as applicable in Pakistan for interim financial reporting. Our responsibility is to express a conclusion on this interim financial information based on our review. The figures of the condensed interim profit and loss account and condensed interim statement of comprehensive income for the quarters ended June 30, 2013 and June 30, 2012 have not been reviewed, as we are required to review only the cumulative figures for the six months ended June 30, 2013.

### Scope of Review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

#### Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial information as of and for the six months ended June 30, 2013 is not prepared, in all material respects, in accordance with approved accounting standards as applicable in Pakistan for interim financial reporting.

M. Youry Adril Lem - Le Chartered Accountants

Engagement Partner Nadeem Yousuf Adil

Place: Karachi

Date: August 19, 2013

Member of

Deloitte Touche Tohmatsu Limited

### Condensed Interim Balance Sheet

As at June 30, 2013

UNAUDITED	A
JUNE 30,	DEC
2013	

AUDITED DECEMBER 31, 2012

Note

----- (Rupees '000) ------

### Non-Current Assets

Non Odirone, todata			
Fixed Assets			0.000.454
- Property, plant and equipment	3	2,956,759	2,629,154
- Intangible asset		50,225	58,835
		3,006,984	2,687,989
Long-term loans and advances		40,121	44,281
Long-term deposits		3,737	3,737
Long-term prepayments		5,912	6,491 54,509
		3,056,754	2,742,498
Total Non-Current Assets		3,036,734	2,742,490
Current Assets			
			101 011
Stores and spares		107,195	121,844
Stock-in-trade		2,761,755	2,426,561
Trade debts		487,196	566,734
Loans and advances - considered good		246,515	123,308
Trade deposits and short-term prepayments		181,521	151,781
Accrued profit		9,435	2,973 80,766
Other receivables		87,978	323,185
Taxation recoverable		206,827	2,790,212
Cash and bank balances		3,044,923 7,133,345	6,587,364
0		7,100,040	0,567,504
Current Liabilities		2,536,942	2,432,911
Trade and other payables		2,536,942	2,432,911
Net Current Assets		4,596,403	4,154,453
Total Assets Less Current Liabilities		7,653,157	6,896,951
Non-Current Liability			
Deferred taxation		180,158	189,557
Contingencies and Commitments	4		
NET ASSETS		7,472,999	6,707,394
HEI / HOUE ! O			
FINANCED BY:			
Share Capital and Reserves			
Authorised capital		2 000 000	2,000,000
200,000,000 ordinary shares of Rs.10 each		2,000,000	2,000,000
Issued, subscribed and paid-up capital	5	979,003	979,003
Decenies conitel		280 422	262,308

The annexed notes 1 to 10 form an integral part of this condensed interim financial information.

ARSHAD SAEED HUSAIN CHIEF EXECUTIVE

Reserves - capital

SHAREHOLDERS' EQUITY

- revenue

SYED ANIS AHMED DIRECTOR

280,422

6,213,574

262,308

5,466,083

6,707,394

## Condensed Interim Profit and Loss Account (Unaudited)

For the Quarter and Six Months Ended June 30, 2013

	Apr - Jun 2013	Jan - Jun 2013	Apr - Jun 2012	Jan - Jun 2012
		(Rupees	s '000)	
Sales - net				
Domestic	4,217,738	7,921,256	3,711,837	7,113,590
Export	162,207	294,061	172,497	308,223
	4,379,945	8,215,317	3,884,334	7,421,813
Service fee for toll manufacturing	1,362	6,900	6,274	8,144
	4,381,307	8,222,217	3,890,608	7,429,957
Cost of goods sold and services	2,615,444	5,053,139	2,378,637	4,574,264
Gross profit	1,765,863	3,169,078	1,511,971	2,855,693
Selling and distribution expenses	638,730	1,223,840	554,916	1,117,462
Administrative expenses	87,177	175,104	83,630	161,693
	1,039,956	1,770,134	873,425	1,576,538
Other operating income	59,543	123,520	42,873	88,536
Other operating charges	102,663	183,491	95,856	158,713
	996,836	1,710,163	820,442	1,506,361
Finance cost	667	1,391	278	697
Profit before taxation	996,169	1,708,772	820,164	1,505,664
Taxation				
- current	311,754	579,080	274,677	493,774
- deferred	4,358	(9,400)	(1,935)	(7,631)
	316,112	569,680	272,742	486,143
Profit for the period	680,057	1,139,092	547,422	1,019,521
		(Ru)	oees)	
Earnings per share - basic / diluted	6.95	11.64	5.59	10.41
		3/2-		

The annexed notes 1 to 10 form an integral part of this condensed interim financial information.

ARSHAD SAEED HUSAIN CHIEF EXECUTIVE

## Condensed Interim Statement of Comprehensive Income (Unaudited)

For the Quarter and Six Months Ended June 30, 2013

	Apr - Jun 2013	Jan - Jun 2013 (Rupee	Apr - Jun 2012 s '000)	Jan - Jun 2012 
Profit for the period	680,057	1,139,092	547,422	1,019,521
Other comprehensive income	-	-	N-2	
Total comprehensive income for the period	680,057	1,139,092	547,422	1,019,521

The annexed notes 1 to 10 form an integral part of this condensed interim financial information.

ARSHAD SAEED HUSAIN CHIEF EXECUTIVE

## Condensed Interim Cash Flow Statement (Unaudited)

### For the Six Months ended June 30, 2013

	Jan - Jun 2013	Jan - Jun 2012
Note	(Rupees 'C	000)
6	1,513,980	1,283,949
	(462,721) 4,160 579	(530,912) (3,267) 2,732
	1,055,998	752,502
	(525,178) 12,657 102,751 (409,770)	(303,506) 16,504 74,179 (212,823)
	(1,391) (390,126)	(697) (391,908)
	(391,517)	(392,605)
	254,711	147,074
eriod	2,790,212	1,453,327
	3,044,923	1,600,401
		2013 Note (Rupees 'Company of the company of

The annexed notes 1 to 10 form an integral part of this condensed interim financial information.

ARSHAD SAEED HUSAIN CHIEF EXECUTIVE

## Condensed Interim Statement of Changes in Equity (Unaudited)

### For the Six Months ended June 30, 2013

		Reserves					
		Capital F	Reserves	Revenue	Reserves		
	Share Capital	Reserve arising on Merger	Other	General Reserve	Un- appropriated Profit	Total	Total Equity
Balance as at December 31, 2011	979.003	46.097	177.150	(Rupees '000) 2,438,422	1,545,511	4,207,180	5,186,183
Transfer from unappropriated profit to general reserve made subsequent to the year ended December 31, 2011	37 0,000	40,037	-	1,150,000	(1,150,000)	4,207,100	5,100,103
Total comprehensive income for the six months ended June 30, 2012							
Profit for the period	-	-	-	-	1,019,521	1,019,521	1,019,521
Other comprehensive income for the period, net of tax	-	-			-	-	-
Total comprehensive income for the period					1,019,521	1,019,521	1,019,521
Transactions with owners, recorded directly in equity							
Final dividend for the year ended December 31, 2011 @ Rs. 4 per share declared subsequent to the year end					(391,601)	(391,601)	(391,601)
Capital contribution from Abbott International LLC, USA	-		19,853			19,853	19,853
Balance as at June 30, 2012	979,003	46,097	197,003	3,588,422	1,023,431	4,854,953	5,833,956
Balance as at December 31, 2012	979,003	46,097	216,211	3,588,422	1,877,661	5,728,391	6,707,394
Transfer from unappropriated profit to general reserve made subsequent to the year ended December 31, 2012				1,750,000	(1,750,000)		
Total comprehensive income for the six months ended June 30, 2013							
Profit for the period	-	-		-	1,139,092	1,139,092	1,139,092
Other comprehensive income for the period, net of tax	-	-	-	′2	-	-	_
Total comprehensive income for the period	-				1,139,092	1,139,092	1,139,092
Transactions with owners, recorded directly in equity							
Final dividend for the year ended December 31, 2012 @ Rs. 4 per share declared subsequent to the year end	-	-		-	(391,601)	(391,601)	(391,601)
Capital contribution from Abbott International LLC, USA		-	18,114	-		18,114	18,114
Balance as at June 30, 2013	979,003	46,097	234,325	5,338,422	875,152	6,493,996	7,472,999

The annexed notes 1 to 10 form an integral part of this condensed interim financial information.

ARSHAD SAEED HUSAIN CHIEF EXECUTIVE

For the Six Months ended June 30, 2013

### 1. THE COMPANY AND ITS OPERATIONS

Abbott Laboratories (Pakistan) Limited (The Company) is a public limited Company incorporated in Pakistan on July 02, 1948, and its shares are quoted on the Karachi, Lahore and Islamabad stock exchanges. The address of its registered office is opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi. The Company is principally engaged in the manufacture, import and marketing of research based pharmaceutical, nutritional, diagnostic, diabetic care, molecular devices, hospital and consumer products and in providing toll manufacturing services.

### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### 2.1 Basis of preparation

#### Statement of compliance

This condensed interim financial information has been prepared in accordance with the requirements of the International Accounting Standard 34 – "Interim Financial Reporting" and provisions of and directives issued under the Companies Ordinance, 1984. In case where requirements differ, the provisions of or directives issued under the Companies Ordinance, 1984 have been followed. This condensed interim financial information does not include all of the information and disclosures required for annual financial statements, and should be read in conjunction with the financial statements of the Company as at and for the year ended December 31, 2012.

This condensed interim financial information is being submitted to the shareholders as required by the Listing Regulations of Karachi, Lahore and Islamabad stock exchanges and section 245 of the Companies Ordinance, 1984.

### 2.2 Accounting policies

The accounting policies and the methods of computation used in the preparation of this condensed interim financial information are the same as those applied in the preparation of the financial statements for the preceding year ended December 31, 2012.

#### 2.3 Accounting estimates and judgments.

The preparation of condensed interim financial information in conformity with approved accounting standards, as applicable in Pakistan requires the management to make estimates, assumptions and use judgments that affect the application of policies and the reported amount of asset, liabilities and income and expenses.

Estimates and judgments made by management in the preparation of this condensed interim financial information are the same as those that were applied to the annual financial statements of the Company as at and for the year ended December 31, 2012.

For the Six Months ended June 30, 2013

UNAUDITED	UNAUDITED
Jan - Jun	Jan - Jun
2013	2012
(Rupe	es '000)

### PROPERTY, PLANT AND EQUIPMENT [COST OF ADDITIONS / (DELETIONS)]

Buildings on freehold land	13,901	-
Plant and machinery	97,462	77,196 (13,520)
Office equipment	-	4,392
Vehicles	18,622 (20,434)	35,448 (23,380)
Computers	56,381	14,350
Demonstration equipment	272,614	91,719
Capital work in progress (CWIP) - net of transfers	66,198	80,401
Total Additions	525,178	303,506
Total (deletions)	(20,434)	(36,900)

### CONTINGENCIES AND COMMITMENTS

#### 4.1 Contingencies

- 4.1.1 The Company has given bank guarantees of Rs. 112.893 million (December 31, 2012: Rs 110.557 million) to the Customs Department, a utility company and other institutions against tenders.
- 4.1.2 The returns of total income for four tax years (Tax Years 2005 2008) were selected for audit by the tax authority. The Taxation Officer disallowed certain expenses claimed by the Company against which the Company filed appeals before the Commissioner Inland Revenue (Appeals) [CIR(A)]. The CIR(A) allowed certain expenses, however, maintained majority of the disallowances resulting in tax demand of Rs. 239.695 million. The Company has now filed the appeals before the Appellate Tribunal Inland Revenue (ATIR) which are pending adjudication.

Management is of the view that the position of the Company is sound and eventual outcome is expected to be in Company's favour. Therefore, no provision has been made in the financial statements.

4.1.3 The Company has filed a reference application before the High Court of Sindh for assessment years 1997-98, 1999-00 to 2002-03 in respect of certain disallowances resulting in a tax demand of Rs 154.500 million, which is pending adjudication.

Management is of the view that the position of the Company is sound and eventual outcome is expected to be in Company's favour. However, being prudent, management has made a total provision of Rs. 120 million in this respect as of June 30, 2013 (December 31, 2012: Rs. 80 million).

For The Six Months Ended June 30, 2013

#### 4.2 Commitments

- 4.2.1 Commitments for capital expenditure as at June 30, 2013 aggregated to Rs. 93.562 million (December 31, 2012: Rs. 127.907 million).
- 4.2.2 The Company has obtained short term financing facilities from various commercial banks amounting to Rs. 1,377 million (December 31, 2012: Rs. 1,372 million). These facilities can be utilized for letters of credit, guarantees and running finance / short term loans. However, the running finance / short term loan utilization cannot exceed Rs. 310 million (December 31, 2012: Rs. 310 million). The running finance / short term loan carries markup at rates ranging from KIBOR plus 1% to KIBOR plus 2% (December 31, 2012: KIBOR plus 1% to KIBOR plus 2%) and are secured against first joint pari passu hypothecation charge over stocks and book debts of the Company, ranking hypothecation charge over stocks and book debts of the Company, promissory notes, and counter guarantees. The Company has not borrowed any amount against running finance / short term loan facilities at the balance sheet date. Commitments in respect of letters of credit as at balance sheet date aggregated to Rs. 509.792 million (December 31, 2012: Rs. 368.054 million).

### 5. ISSUED, SUBSCRIBED AND PAID-UP CAPITAL

As at June 30, 2013, Abbott Asia Investments Limited, UK held 76,259,454 (December 31, 2012: 76,259,454) shares. The ultimate holding company is Abbott International LLC, USA.

		Note	UNAUDITED Jan - Jun 2013 (Rupee	UNAUDITED Jan - Jun 2012 s '000)
6.	CASH GENERATED FROM OPERATIONS			
	Profit before taxation		1,708,772	1,505,664
	Adjustment for:			
	Depreciation Amortisation on intangible asset Gain on disposal of fixed assets Income on investments and deposits		188,146 8,610 (3,230) (109,213)	148,664 8,610 (6,773) (74,895)
	Expense recognised in profit or loss in respect of equity-settled share-based payments Finance cost Working capital changes	6.1	18,114 1,391 (298,610)	19,853 697 (317,871)
			1,513,980	1,283,949
6.1	Working capital changes			
	(Increase) / decrease in current assets net of pro-	vision		
	Stores and spares Stock-in-trade Trade debts Loans and advances Trade deposits and short-term prepayments Other receivables Increase in current liabilities		14,649 (335,194) 79,538 (123,207) (29,740) (7,212) (401,166)	(4,566) (532,894) (36,633) (69,957) (33,792) (713,298)
	Trade and other payables - net		102,556 (298,610)	<u>395,427</u> (317,871)
			[230,010]	

For The Six Months Ended June 30, 2013

### 7. TRANSACTIONS WITH RELATED PARTIES

The related parties of the Company comprise other related parties, employee retirement benefit plans, directors and key management personnel. Transactions with related parties essentially entail sale and purchase of goods and services and expenses charged between these parties. Transactions with related parties are as follows:

	Jan - Jun 2013 (Rupe	UNAUDITED Jan - Jun 2012 es '000)
Other related parties		
Sale of goods Purchase of materials Technical service fee	49,496 1,711,366 58,595	27,575 1,440,766 54,011
Reimbursements from a related party on account of:		
<ul> <li>Selling and distribution expenses</li> <li>Administrative expenses</li> </ul>	34,505 3,673	31,276 4,128
Interest income earned	9,296	7,596
Charge in respect of staff retirement benefit plans:		
Pension fund Provident fund	59,291 29,079	51,714 25,412
Key management personnel		
Short-term employee benefits Post-employment benefits	84,032 9,108	81,745 8,349

### 8.1 Segment wise operating results for the second quarter:

SEGMENT ANALYSIS

		UNAUDI	TED			UNAUDI	TED	
		Apr - Jun				Apr - Ji		
	-	2013			2012			
	Pharmaceutical	Nutritional	Others	Total	Pharmaceutical	Nutritional	Others	Total
				(Rupee	es '000)			*********
Sales	3,321,750	697,748	476,211	4,495,709	2,943,541	545,490	513,098	4,002,129
Less:								
Sales return and discount	9,046	1	1,155	10,202	20,504	1,594	2,656	24,754
Sales tax and excise duty	-	63,598	41,964	105,562	-	48,787	44,254	93,041
Sales - net	3,312,704	634,149	433,092	4,379,945	2,923,037	495,109	466,188	3,884,334
Service fee for toll manufacturing	2	2	1,362	1,362	2,249	-	4,025	6,274
	3,312,704	634,149	434,454	4,381,307	2,925,286	495,109	470,213	3,890,608
Cost of goods sold and services	1,937,659	397,955	279,830	2,615,444	1,800,064	310,106	268,467	2,378,637
Gross profit	1,375,045	236,194	154,624	1,765,863	1,125,222	185,003	201,746	1,511,971
Selling and distribution expenses	466,486	89,221	83,023	638,730	405,099	83,147	66,670	554,916
Administrative expenses	70,789	13,262	3,126	87,177	69,777	10,211	3,642	83,630
Segment result	837,770	133,711	68,475	1,039,956	650,346	91,645	131,434	873,425

For The Six Months Ended June 30, 2013

## 8.2 Segment wise operating results for six months ended:

Segment wisc opera			-			UNAUDITE	ED	
		Jan - Jur				Jan - Jur	1	
	2013				No. all	2012 Nutritional	Others	Total
	Pharmaceutical	Nutritional	Others	Total (Rupee	Pharmaceutical (1000)	Nutritional	Othoro	
Sales	6,148,607	1,319,324	969,585	8,437,516	5,697,945	1,042,168	901,494	7,641,607
Less: Sales return and discount	16,970	3,320 119,625	1,886 80,398	22,176 200,023	36,740	6,592 94,967	3,635 77,860	46,967 172,827
Sales tax and excise duty  Sales - net	6,131,637	1,196,379	887,301 6,900	8,215,317 6,900	5,661,205 2,249	940,609	819,999 5,895	7,421,813 8,144
Service fee for toll manufacturing  Cost of goods sold and services	6,131,637	1,196,379 748,080	894,201 560,678	8,222,217 5,053,139	5,663,454 3,542,540	940,609 558,414	825,894 473,310	7,429,957 4,574,264
Cost of goods sold and services  Gross profit  Selling and distribution expenses  Administrative expenses	2,387,256	448,299 187,552	333,523 143,393 6,564	3,169,078 1,223,840 175,104	2,120,914 830,337 133,921	382,195 154,902 21,103	352,584 132,223 6,669	2,855,693 1,117,462 161,693
Segment result	1,351,209	235,359	183,566	1,770,134	1,156,656	206,190	213,692	1,576,53

## 8.3 Reconciliation of segment results with profit before taxation

110001011111111111111111111111111111111	UNAUDITED Apr - Jun 2013	UNAUDITED Jan - Jun 2013	UNAUDITED Apr - Jun 2012 es '000)	UNAUDITED Jan - Jun 2012	
Total segment results Other operating income Other operating charges Finance cost	1,039,956 59,543 102,663 667	1,770,134 123,520 183,491 1,391	873,425 42,873 95,856 278	1,576,538 88,536 158,713 697	
Profit before taxation	996,169	1,708,772	820,164	1,505,664	

### 8.4 Geographical information

Sales to external customers

	UNAUDITED Apr - Jun 2013	UNAUDITED Jan - Jun 2013 (Rupee	UNAUDITED Apr - Jun 2012 es '000)	UNAUDITED Jan - Jun 2012
Pakistan Afghanistan Srilanka Netherland Bangladesh	4,219,100 134,006 10,298 17,903	7,928,156 226,738 13,992 49,496 3,835	3,718,111 128,041 25,997 14,892 3,567	7,121,734 233,488 43,593 27,575 3,567
Dailgiadeoit	4,381,307	8,222,217	3,890,608	7,429,957

For The Six Months Ended June 30, 2013

### 8.5 Segment Assets

	UNAUDITED June 30, 2013			AUDITED  December 31, 2012				
	Pharmaceutical	Nutritional	Others	Total	Pharmaceutical	Nutritional	Others	Total
				(Rupe	es '000)			
Segment assets employed	5,186,108	381,576	1,011,211	6,578,895	4,723,188	254,297	745,981	5,723,466
Unallocated corporate assets				3,611,204				3,606,396
Total reported assets				10,190,099				9,329,862

### 9. NON ADJUSTING EVENT AFTER THE BALANCE SHEET DATE

The Directors in their meeting held on August 19, 2013 have proposed an interim cash dividend @ 30 % (June 30, 2012: 30%). This condensed interim financial information for the six months ended June 30, 2013 does not include the effect of the above interim cash dividend which will be accounted for subsequent to the period end.

### 10. DATE OF AUTHORISATION

This condensed interim financial information was authorised for issue on August 19, 2013 by the Board of Directors of the Company.

ARSHAD SAEED HUSAIN CHIEF EXECUTIVE

### ABBOTT LABORATORIES (PAKISTAN) LIMITED

### Registered Office

Opposite Radio Pakistan
Transmission Centre, Hyderabad Road,
Landhi, P.O. Box 7229, Karachi
Phone :111-ABBOTT (111-222-688)
Fax: (92-21) 35001903

### City Office

8th Floor, Faysal House, St-02, Shahrah-e-Faisal, Karachi Phone: (92-21) 32799018, 32799019 Fax: (92-21) 32800244 URL: www.abbott.com.pk

